Orphan diseases and drugs [4]

Indian Journal of Pharmacology

Volumn 38, Issue 4, 2006, Pages 299-300

  Badyal, D ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ORPHAN DRUG; PENICILLAMINE; TRIENTINE; VACCINE; ZINC;

DRUG CLASSIFICATION; DRUG CONTROL; DRUG INDICATION; DRUG MANUFACTURE; DRUG USE; ECONOMIC ASPECT; LETTER; MALARIA; TUBERCULOSIS;

EID: 33747589887     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.27036     Document Type: Letter

References (6)

1. Thielke D, Thyssen JP, Hansen BJ. Orphan drugs: medications for patients with rare diseases Ugeskr Laeger 2006;168:2236-8.
2. Grabowski H. Encouraging the development of new vaccines. Health Aff 2005;24:697-700.
3. FDA grants orphan drug status to genotropin (somatropin) for growth failure in small for gestational age children; 2006. Available from: http:// www.pslgroup.com/dg/201F5E.htm
4. Spilker B. Orphan drugs. In: Comprehensive medicinal chemistry. Kennewell PD, editor. Vol 1. Oxford: Pergamon Press; 1990. p. 667-74.
5. Joglekar P, Paterson ML. A closer look at the returns and risk of pharmaceutical R&D. J Health Econ 1986;5:153-77.
6. Haffner ME. Adopting orphan drugs: two dozen years of treating rare diseases. New Engl J Med 2006;354:445-7.